0001213900-24-031700.txt : 20240409
0001213900-24-031700.hdr.sgml : 20240409
20240409204930
ACCESSION NUMBER: 0001213900-24-031700
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240405
FILED AS OF DATE: 20240409
DATE AS OF CHANGE: 20240409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shakil Ian
CENTRAL INDEX KEY: 0001826129
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40890
FILM NUMBER: 24834013
MAIL ADDRESS:
STREET 1: C/O AUGMEDIX, INC.
STREET 2: 1161 MISSION STREET, SUITE LL
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Augmedix, Inc.
CENTRAL INDEX KEY: 0001769804
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
ORGANIZATION NAME: 07 Trade & Services
IRS NUMBER: 833299164
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 SUTTER STREET, SUITE 1300
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 561-989-2208
MAIL ADDRESS:
STREET 1: 111 SUTTER STREET, SUITE 1300
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
FORMER COMPANY:
FORMER CONFORMED NAME: Malo Holdings Corp
DATE OF NAME CHANGE: 20190305
4
1
ownership.xml
X0508
4
2024-04-05
0
0001769804
Augmedix, Inc.
AUGX
0001826129
Shakil Ian
C/O AUGMEDIX, INC.
111 SUTTER STREET, SUITE 1300
SAN FRANCISCO
CA
94104
1
1
0
0
CHIEF STRATEGY OFFICER
1
Common Stock
2024-04-05
4
S
0
51387
4.0328
D
12217
D
Common Stock
2024-04-08
4
M
0
28563
0.64
A
40780
D
Common Stock
2024-04-08
4
S
0
28563
3.9695
D
12217
D
Common Stock
2024-04-08
4
S
0
9217
3.9695
D
3000
D
Stock Option (Right to Buy)
0.64
2024-04-08
4
M
0
28563
0
D
2030-06-03
Common Stock
28563
14356
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades ranging from $3.9400 to $4.1700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Fully vested.
/s/ Todd Holvick, Attorney-in-Fact
2024-04-09